Company Overview
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -21.08% |
| 6 Months: | -24.06% |
| 3 Months: | -4.17% |
| 1 Month: | +0.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 43.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONCY Oncolytics Biotech Inc. PHARMA | 0.80 | -2.29 | $102.01M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 4.89M | 4.17M | 9.94M | 9.65M | 9.28M |
| Operating Income | - | -4.89M | -4.17M | -9.94M | -9.65M | -9.28M |
| EBITDA | - | -4.82M | -4.10M | -9.88M | -9.65M | -9.27M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -4.67M | -4.44M | -10.53M | -8.98M | -9.24M |
| Tax Provision | 11.38K | - | 62.12K | -181.07K | 198.99K | - |
| Net Income | - | -4.67M | -4.51M | -10.35M | -9.18M | -9.24M |
| Diluted EPS | - | -0.06 | -0.05 | -0.10 | - | -0.08 |
| R&D Expense | - | 2.80M | - | - | - | 4.55M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 19.84M | 25.47M | 24.37M | 28.73M |
| Operating Income | - | -19.84M | -25.47M | -24.37M | -28.73M |
| EBITDA | - | -19.55M | -25.17M | -24.08M | -28.66M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -18.24M | -20.85M | -22.00M | -28.68M |
| Tax Provision | - | 61.89K | 73.12K | 90.58K | 79.00K |
| Net Income | - | -18.30M | -20.92M | -22.09M | -28.76M |
| Diluted EPS | - | -0.32 | -0.31 | -0.29 | -0.30 |
| R&D Expense | - | - | - | 15.44M | 13.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 27.51M | 29.26M | 14.07M | 7.58M |
| Current Assets | - | 26.29M | 28.78M | 13.15M | 6.84M |
| Cash & Equivalents | - | 8.60M | 26.32M | 11.11M | 5.20M |
| Inventory | - | - | - | - | - |
| Receivables | - | 383.88K | 11.31K | 47.38K | 573.00K |
| Total Liabilities | - | 7.98M | 8.49M | 9.90M | 11.38M |
| Current Liabilities | - | 2.91M | 3.19M | 4.66M | 6.10M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 274.83K | 318.86K | 741.37K | 563.00K |
| Total Equity | - | 19.53M | 20.78M | 4.17M | -3.80M |
| Shares Outstanding | - | 61.33M | 74.42M | 80.02M | 108.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -17.21M | -21.44M | -18.79M | -20.11M |
| Investing Cash Flow | - | -15.03M | 15.24M | -166.53K | -6.00K |
| Financing Cash Flow | - | 8.99M | 24.12M | 4.62M | 14.12M |
| Capital Expenditure | - | -40.52K | -6.03K | -166.53K | -6.00K |
| Free Cash Flow | - | -17.25M | -21.45M | -18.96M | -20.12M |
| Net Change in Cash | - | -23.25M | 17.92M | -14.33M | -6.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -93.7% | -100.7% | -530.0% | 757.0% |
| ROCE % | - | -80.6% | -97.7% | -259.1% | -1,939.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Marshall Wace LLP | 0.58% | 745.35K | $573.92K |
| 2 | Seeds Investor LLC | 0.20% | 258.31K | $198.90K |
| 3 | Xtx Topco Ltd | 0.20% | 260.90K | $200.90K |
| 4 | International Assets Investment Management, LLC | 0.16% | 201.26K | $154.97K |
| 5 | Connective Capital Management LLC | 0.15% | 185.71K | $143.00K |
| 6 | Goldman Sachs Group Inc | 0.13% | 169.90K | $130.82K |
| 7 | Tocqueville Asset Management L.p. | 0.12% | 147.00K | $113.19K |
| 8 | Everhart Financial Group, Inc. | 0.11% | 140.90K | $108.49K |
| 9 | Susquehanna International Group, LLP | 0.11% | 134.13K | $103.28K |
| 10 | Pfg Investments, LLC | 0.10% | 128.30K | $98.79K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONCY
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOb1pJaWhDRjJFbTlFUlo2dW5WSVA1STNuaUs0VlJ6ZUt6cDJ1WjFUT2IzTFFfcHJEbXhNZDFqS3VXQ2ZMQXhYWmNRWG11d3VYTlJ5dF8zcVV4Y2tKczBsb2JEQmVmeHAya3Q3SzllaDMxZC1iS2VtZ3A3NjUtVkJ4WTltZ3JuX2g0cllORk…
ONCY Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1WVjBpa1FzVUhqVlJabTdiNjRPQk9OVDNiX1VhVDlMRkpWU2tybUNZal9PMEFoQi1fYkp5Y1lKLXBzM1VncWxDelVONUZfYklseElWOFphVVFfc1c5cnlrdThsd3RZbjBfelhvU1laUmphNFEzZ0EzS0R3?oc=5" target="_blank">ONC…
Investigational anal cancer therapy posts 30% response rate - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPOE00NFN5ZHdjY2JNOXQ2T2RFcEJaQWF3VDdHbndBazBKUnVWVEJVbnJmcFRaUHptRk5FS1FMaEVyLWRoaXVuTWc1d19HUEY5VnYycExadmppdmRuSDFWUXVBa3NZUkdOQVhCLVN5b1B4bHVWSU1za3M2VU13enl1REFIZmozdjV0dmUwaT…
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQUVNWV0tmYUo5SWlkNjNSZ3JMRjNZZXptbk9ELXAtYVJSNmhiYWh5Wl80VXZNUDRyY1QwRXh1OUZvbVZSZ2EydC1iQ0lWOVRmNTB5S3BuLUUtN18yM1p5RTFvWHNKWUR2Z0NKaGpZU1lTT0ZtTFBuVnQtV2UwZzBXUFpKQjlXRHlEUzkyZ3…
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZXZONVY3RFBrVVRQUk50MEwxa2JPLUV2R0xUWmZaRVA0YjJlLTgxQUdkUm9RLXhlTFZ3bkptb2JZSGhqWDZvUWFxdDBlV2dTU21qeVVEc3RRXzBqNmcwV0dwYXVUWUJWMFNJakRLQWRzWEpFZC1QZFh5R3FqbFRyeHZsa01ub21MT3JIMW…
$ONCY stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOcnV4MUtxbWN6aFZtZi1DWUl1LXR5a01oZTZpNW1TR3Jla0wzMlZJZGpRVUJlWXlxQVNabFpzX2RpS1FNa3B6UDF4YzBMUWtuU1BETUllWElOWTRGaDFMV1JkWkZCQzFtY3drMEhsZHZwbE9IWkloazhnVjF2anFvYTE3R2swNjFxc0NzRk…
ONCY — Frequently Asked Questions
What is the current share price of Oncolytics Biotech Inc. (ONCY)?
As of 2026-09-19 21:16 PDT, Oncolytics Biotech Inc. (ONCY) trades at $0.80 on NasdaqCM. Its 52-week range is $0.75 to $1.42.
What is the market capitalisation of ONCY?
Oncolytics Biotech Inc. (ONCY) has a market capitalisation of $102.01M on NasdaqCM.
What is the P/E ratio of ONCY?
ONCY trades at a trailing price-to-earnings (P/E) ratio of -2.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -15.71.
Is ONCY a good stock to buy?
This page provides a data-driven analysis of Oncolytics Biotech Inc. (ONCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.